I agree that this site is using cookies. You can find further informations here.
X
Naleid, Nikolas
8  results:
Search for persons X
?
1

Atezolizumab plus bevacizumab as first-line systemic therap..:

Storandt, Michael H ; Zemla MS, Tyler J ; Patell, Kanchi...
The Oncologist.  , 2024
Link: https://doi.org/10.1093/..
 
?
2

Circulating Tumor DNA Predicts Early Recurrence Following L..:

O'Donnell, Conor D. J. ; Naleid, Nikolas ; Siripoon, Teerada...
Cancers.  16 (2024)  13 - p. 2407 , 2024
Link: https://doi.org/10.3390/..
 
?
3

POSTER: MM-537 Impact of Melphalan Dose and CD34+ Cell Infu..:

Kort, Jeries ; Oley, Frank ; Naleid, Nikolas...
Clinical Lymphoma Myeloma and Leukemia.  23 (2023)  - p. S222 , 2023
Link: https://doi.org/10.1016/..
 
?
4

MM-537 Impact of Melphalan Dose and CD34+ Cell Infusion on ..:

Kort, Jeries ; Oley, Frank ; Naleid, Nikolas...
Clinical Lymphoma Myeloma and Leukemia.  23 (2023)  - p. S508 , 2023
Link: https://doi.org/10.1016/..
 
?
5

Dose Adjustment of Melphalan Is Safe and Effective for Cert..:

Kort, Jeries ; Oley, Frank ; Naleid, Nikolas...
Transplantation and Cellular Therapy.  29 (2023)  2 - p. S406 , 2023
Link: https://doi.org/10.1016/..
 
?
6

Nodular Lymphocyte-Predominant Hodgkin Lymphoma: Review of ..:

Sidda, Adarsh ; Naleid, Nikolas Kristopher ; Manu, Gurusidda..
Journal of Investigative Medicine High Impact Case Reports.  10 (2022)  - p. 232470962211117 , 2022
Link: https://doi.org/10.1177/..
 
?
7

Nodular Lymphocyte-Predominant Hodgkin Lymphoma: Review of ..:

Sidda, Adarsh ; Naleid, Nikolas Kristopher ; Manu, Gurusidda..
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9309769/.  , 2022
Link: http://www.ncbi.nlm.nih...
 
?
8

Nodular Lymphocyte-Predominant Hodgkin Lymphoma: Review of ..:

Adarsh Sidda MD ; Nikolas Kristopher Naleid MD ; Gurusidda Manu MD..
https://doi.org/10.1177/23247096221111767.  , 2022
Link: https://doi.org/10.1177/..
 
1-8